Correspondence 0001213900-22-079844 from Scinai Immunotherapeutics Ltd. (SCNI)
Scinai Immunotherapeutics Ltd.
Date: Dec. 14, 2022 · CIK: 0001611747 · Accession: 0001213900-22-079844
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-267648
Letter
Re: BiondVax Pharmaceuticals Ltd.
AEGIS CAPITAL CORP.
December 14, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street NE
Washington, D.C. 20549
Registration Statement on Form F-1
File No. 333-267648
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Securities Act”), Aegis Capital Corp. hereby joins BiondVax Pharmaceuticals Ltd. in requesting that the Securities and Exchange Commission take appropriate action to accelerate the effective date of the above-referenced registration statement on Form F-1, as amended, so as to become effective on Thursday, December 15, at 4:15 PM Eastern Time, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act, please be advised that we will distribute as many electronic copies of the proposed form of preliminary prospectus as it appears to be reasonable to secure adequate distribution.
Very truly yours,
Aegis Capital Corp.
Show Raw Text
CORRESP
1
filename1.htm
AEGIS CAPITAL CORP.
December 14, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street NE
Washington, D.C. 20549
Re:
BiondVax Pharmaceuticals Ltd.
Registration Statement on Form F-1
File No. 333-267648
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations
under the Securities Act of 1933, as amended (the “Securities Act”), Aegis Capital Corp. hereby joins BiondVax Pharmaceuticals
Ltd. in requesting that the Securities and Exchange Commission take appropriate action to accelerate the effective date of the above-referenced
registration statement on Form F-1, as amended, so as to become effective on Thursday, December 15, at 4:15 PM Eastern Time, or as soon
thereafter as practicable.
Pursuant to Rule 460 under the Securities Act, please
be advised that we will distribute as many electronic copies of the proposed form of preliminary prospectus as it appears to be reasonable
to secure adequate distribution.
Very truly yours,
Aegis Capital Corp.
/s/ Robert J. Eide
Robert J. Eide
Chief Executive Officer
810 Seventh Avenue, 18th
floor, New York, New York 10019 (212) 813-1010/Fax (212) 813-1047
Member FINRA, SIPC